Advanced search
Publication Cover
Aging Health Volume 2, 2006 - Issue 3
Journal homepage
78
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

The Role of Alfuzosin in the Treatment of Benign Prostate Hyperplasia and Acute Urinary Retention

Steve KW Leung1 Department of Urology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK Tel.: +44 (0)131 332 2471; Fax: +44 (0)131 467 8450; E-mail: [email protected]
&
S Alan McNeill2 E-mail: [email protected]
Pages 363-369 | Published online: 24 May 2006

Bibliography

  • Berry SJ , CoffeyDS, WalshPC, EwingLL: The development of human benign prostatic hyperplasia with age.J. Urol.132(3), 474–479(1984).
  • Wilson JD : The pathogenesis of benign prostatic hyperplasia.Am. J. Med.68(5), 745–756(1980).
  • Shapiro E , BecichMJ, HartantoV, Lepor H: The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J. Urol.147(5), 1293–1297(1992).
  • Roehrborn CG , BartschG, KirbyRet al.: Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview.Urology58(5), 642–650(2001).
  • Calais Da Silva F, Marquis P, Deschaseaux P et al.: Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur. Urol.31(3), 272–280(1997).
  • Clifford GM , FarmerRD: Medical therapy for benign prostatic hyperplasia: a review of the literature.Eur. Urol.38(1), 2–19(2000).
  • Caine M , RazS, ZeiglerM: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck.Br. J. Urol.47(2), 193–202(1975).
  • Caine M , PerlbergS, MeretykS: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction.Br. J. Urol.50(7), 551–554(1978).
  • Bylund DB , EikenbergDC, HiebleJPet al.: International Union of Pharmacology nomenclature of adrenoceptors.Pharmacol. Rev.46(2), 121–136(1994).
  • Marshall I , BurtRP, ChappleCR: Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype.Br. J. Pharmacol.115(5), 781–786(1995).
  • Chapple CR , AubryML, JamesSet al.: Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation.Br. J. Urol.63(5), 487–496(1989).
  • Price DT , SchwinnDA, LomasneyJWet al.: Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate.J. Urol.150(2 Pt 1), 546–551(1993).
  • Walden PD , GerardiC, LeporH: Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate.J. Urol.161(2), 635–640(1999).
  • Forray C , BardJA, WetzelJMet al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.Mol. Pharmacol.45(4), 703–708(1994).
  • Djavan B , ChappleC, MilaniS, Marberger M: State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology64(6), 1081–1088(2004).
  • Debruyne FM : Alpha blockers: are all created equal?Urology56(5 Suppl. 1), 20–22(2000).
  • Caine M , PerlbergS, ShapiroA: Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases.Urology17(6), 542–546(1981).
  • Akduman B , CrawfordED: Terazosin, doxazosin, and prazosin: current clinical experience.Urology58(6 Suppl. 1), 49–54(2001).
  • Michel MC , FlanneryMT, NarayanP: Worldwide experience with alfuzosin and tamsulosin.Urology58(4), 508–516(2001).
  • Noble AJ , Chess-WilliamsR, CouldwellCet al.: The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br. J. Pharmacol.120(2), 231–238(1997).
  • Lepor H : Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.Urology51(6), 892–900(1998).
  • Forray C , NobleSA: Subtype selective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia.Expert Opin. Investig. Drugs8(12), 2073–2094(1999).
  • Lefevre-Borg F , O‘ConnorSE, Schoemaker H et al.: Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. Br. J. Pharmacol.109(4), 1282–1289(1993).
  • Martin DJ , AngelI, ArbillaS: Functional uroselectivity.Eur. Urol.33(Suppl. 2), 12–18(1998).
  • Rouquier L , ClaustreY, BenavidesJ: Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study.Eur. J. Pharmacol.261(1–2), 59–64(1994).
  • Wilde MI , FittonA, McTavishD: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.Drugs45(3), 410–429(1993).
  • Teillac P , Delauche-CavallierMC, AttaliP: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.Br. J. Urol.70(1), 58–64(1992).
  • Rauch C , AhtoyP, Pinquier J-L et al.: Bioequivalence of a new once-a-day controlled-release alfuzosin formulation with the immediate-release alfuzosin. Eur. J. Urol.37(Suppl. 2), 119 (2000).
  • McKeage K , PloskerGL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.Drugs62(4), 633–653(2002).
  • Nordling J : Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.BJU Int.95(7), 1006–1012(2005).
  • Roehrborn CG : Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.Urology58(6), 953–959(2001).
  • van Kerrebroeck P , JardinA, LavalKU, van CanghP: Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.Eur. Urol.37(3), 306–313(2000).
  • van Kerrebroec P , JardinA, van Cangh P, Laval KU: Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur. Urol.41(1), 54–60; discussion 60–61(2002).
  • Lukacs B , GrangeJC, CometD, McCarthy C: Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostatic Dis.1(5), 276–283(1998).
  • Buzelin JM , RothS, Geffriaud-RicouardC, Delauche-CavallierMC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.Eur. Urol.31(2), 190–198(1997).
  • Rosen R , AltweinJ, BoylePet al.: Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7).Eur. Urol.44(6), 637–649(2003).
  • van Moorselaar RJ , HartungR, Emberton M et al.: Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int.95(4), 603–608(2005).
  • Buzelin JM , HebertM, BlondinP: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.Br. J. Urol.72(6), 922–927(1993).
  • Buzelin JM , FonteyneE, KontturiM, WitjesWP, KhanA: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.Br. J. Urol.80(4), 597–605(1997).
  • Hofner K , H Claes H, De Reijke TM, Folkestad B, Speakman MJ: Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol.36(4), 335–341(1999).
  • Jacobsen SJ , JacobsonDJ, GirmanCJet al.: Natural history of prostatism: risk factors for acute urinary retention.J. Urol.158(2), 481–487(1997).
  • Emberton M , AnsonK: Acute urinary retention in men: an age old problem.Br. Med. J.318(7188), 921–925(1999).
  • Pickard R , EmbertonM, NealDE: The management of men with acute urinary retention. National Prostatectomy Audit Steering Group.Br. J. Urol.81(5), 712–720(1998).
  • Taube M , GajrajH: Trial without catheter following acute retention of urine.Br. J. Urol.63(2), 180–182(1989).
  • McNeill SA , DaruwalaPD, MitchellID, ShearerMG, HargreaveTB: Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.BJU Int.84(6), 622–627(1999).
  • Lucas MG , StephensonTP, NargundV: Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.BJU Int.95(3), 354–357(2005).
  • McNeill SA , HargreaveTB, RoehrbornCG: Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.Urology65(1), 83–89; discussion 89–90(2005).
  • McConnell JD , RoehrbornCG, Bautista OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med.349(25), 2387–2398(2003).
  • Debruyne FM , JardinA, ColloiDet al.: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.Eur. Urol.34(3), 169–175(1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.